Lupus and hormonesVAN VOLLENHOVEN, Ronald F.Annales de médecine interne (Paris). 1996, Vol 147, Num 4, issn 0003-410X, 58 p.Serial Issue

Oral contraceptives in women with systemic lupus erythematosusBUYON, J. P.Annales de médecine interne (Paris). 1996, Vol 147, Num 4, pp 259-264, issn 0003-410XArticle

Hormones and lupus : defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosusSUZUKI, N; SUZUKI, T; SAKANE, T et al.Annales de médecine interne (Paris). 1996, Vol 147, Num 4, pp 248-252, issn 0003-410XArticle

Neurospychiatric lupus and hormonesROBINSON, T; NEUWELT, C. M.Annales de médecine interne (Paris). 1996, Vol 147, Num 4, pp 276-280, issn 0003-410XArticle

A patient with severe CNS lupus during pregnancyKUZIS, C. S; DRUZIN, M. L; LAMBERT, R. E et al.Annales de médecine interne (Paris). 1996, Vol 147, Num 4, pp 274-275, issn 0003-410XArticle

Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense depositsJONSDOTTIR, Thorunn; SUNDELIN, Birgitta; WELIN HENRIKSSON, Elisabet et al.Annals of the rheumatic diseases. 2011, Vol 70, Num 6, pp 1172-1173, issn 0003-4967, 2 p.Article

Improvement in Work Place and Household Productivity for Patients With Early Rheumatoid Arthritis Treated With Adalimumab Plus Methotrexate: Work Outcomes and Their Correlations With Clinical and Radiographic Measures From a Randomized Controlled Trial Companion StudyVAN VOLLENHOVEN, Ronald F; CIFALDI, Mary A; RAY, Saurabh et al.Arthritis care and research. 2010, Vol 62, Num 2, pp 226-234, issn 0893-7524, 9 p.Article

Systemic lupus erythematosus and pregnancyDRUZIN, M. L; VAN VOLLENHOVEN, R. F.Annales de médecine interne (Paris). 1996, Vol 147, Num 4, pp 265-273, issn 0003-410XArticle

Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosusVAN VOLLENHOVEN, R. F; MCGUIRE, J. L.Annales de médecine interne (Paris). 1996, Vol 147, Num 4, pp 290-296, issn 0003-410XArticle

Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohortsJONSDOTTIR, Thórunn; GUNNARSSON, Iva; MOURAO, Ana Filipa et al.Rheumatology (Oxford. Print). 2010, Vol 49, Num 8, pp 1502-1504, issn 1462-0324, 3 p.Article

Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis: A Randomized TrialERIKSSON, Jonas K; NEOVIUS, Martin; BRATT, Johan et al.JAMA internal medicine (Print). 2013, Vol 173, Num 15, pp 1407-1414, issn 2168-6106, 8 p.Article

Effect of Certolizumab Pegol With Methotrexate on Home and Work Place Productivity and Social Activities in Patients With Active Rheumatoid ArthritisKAVANAUGH, Arthur; SMOLEN, Josef S; EMERY, Paul et al.Arthritis care and research. 2009, Vol 61, Num 11, pp 1598-1606, issn 0893-7524, 9 p.Article

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritisGUNNARSSON, Iva; SUNDELIN, Birgitta; JONSDOTTIR, Thorunn et al.Arthritis and rheumatism. 2007, Vol 56, Num 4, pp 1263-1272, issn 0004-3591, 10 p.Article

Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritisFISHER, Benjamin A; PLANT, Darren; BRODE, Monica et al.Annals of the rheumatic diseases. 2011, Vol 70, Num 6, pp 1095-1098, issn 0003-4967, 4 p.Article

Tofacitinib versus Methotrexate in Rheumatoid ArthritisEUN BONG LEE; FLEISCHMANN, Roy; ZWILLICH, Samuel H et al.The New England journal of medicine. 2014, Vol 370, Num 25, pp 2377-2386, issn 0028-4793, 10 p.Article

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialSTRAND, Vibeke; SMOLEN, Josef S; VAN VOLLENHOVEN, Ronald F et al.Annals of the rheumatic diseases. 2011, Vol 70, Num 6, pp 996-1002, issn 0003-4967, 7 p.Article

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritisBUCH, Maya H; SMOLEN, Josef S; MARIETTE, Xavier et al.Annals of the rheumatic diseases. 2011, Vol 70, Num 6, pp 909-920, issn 0003-4967, 12 p.Article

Ten years with biologics: to whom do data on effectiveness and safety apply?SIMARD, Julia F; ARKEMA, Elizabeth V; LINDBLAD, Staffan et al.Rheumatology (Oxford. Print). 2011, Vol 50, Num 1, pp 204-213, issn 1462-0324, 10 p.Article

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment : Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trialEMERY, Paul; FLEISCHMANN, Roy; HESSEY, Eva W et al.Arthritis and rheumatism. 2006, Vol 54, Num 5, pp 1390-1400, issn 0004-3591, 11 p.Article

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical TrialsVAN VOLLENHOVEN, Ronald F; EMERY, Paul; BINGHAM, Clifton O et al.Journal of rheumatology. 2010, Vol 37, Num 3, pp 558-567, issn 0315-162X, 10 p.Article

The Selective Estrogen Receptor α Agonist Org 37663 Induces Estrogenic Effects but Lacks Antirheumatic Activity: A Phase IIa Trial Investigating Efficacy and Safety of Org 37663 in Postmenopausal Female Rheumatoid Arthritis Patients Receiving Stable Background Methotrexate or SulfasalazineVAN VOLLENHOVEN, Ronald F; HOUBIERS, Jos G. A; SIERAKOWSKI, Stanislaw et al.Arthritis and rheumatism. 2010, Vol 62, Num 2, pp 351-358, issn 0004-3591, 8 p.Article

Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritisDERVIEUX, Thierry; WESSELS, Judith A. M; KREMER, Joel M et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 1, pp 1-9, issn 1744-6872, 9 p.Article

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesCHATZIDIONYSIOU, Katerina; LIE, Elisabeth; PAVELKA, Karel et al.Annals of the rheumatic diseases. 2011, Vol 70, Num 9, pp 1575-1580, issn 0003-4967, 6 p.Article

Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti―Tumor Necrosis Factor α Therapies: Does the Risk Change With the Time Since Start of Treatment?ASKLING, Johan; VAN VOLLENHOVEN, Ronald F; JACOBSSON, Lennart T et al.Arthritis and rheumatism. 2009, Vol 60, Num 11, pp 3180-3189, issn 0004-3591, 10 p.Article

Time-dependent increase in risk of hospitalisation with infection among swedish RA patients treated with TNF antagonistsASKLING, Johan; FORED, C. Michael; LYSHOLM, Jörgen et al.Annals of the rheumatic diseases. 2007, Vol 66, Num 10, pp 1339-1344, issn 0003-4967, 6 p.Article